Soliris® (eculizumab) Net Product Sales Increased 35 Percent to
Continued Steady Soliris Growth Globally in PNH
aHUS Launch Progresses in US and Europe
Guidance Revised Upward for 2013 Revenues and Non-GAAP EPS
Strong Progress in HPP, NMO, Transplant and Other Pipeline Programs
Q2 2013 net product sales increased 35 percent to $370.1 million,
compared to $274.7 million in Q2 2012.
Q2 2013 GAAP net income increased 164 percent to $95.9 million, or
$0.48 per share, compared to Q2 2012 GAAP net income of $36.3 million,
or $0.18 per share. Q2 2012 GAAP net income included $21.8 million of
tax expense related to structuring of the Enobia acquisition.
Q2 2013 non-GAAP net income increased 56 percent to $147.2 million, or
$0.73 per share, compared to Q2 2012 non-GAAP net income of $94.1
million, or $0.47 per share.
Second Quarter 2013 Financial Highlights:
CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial
results for the three and six months ended June 30, 2013. The Company
reported net product sales of Soliris® (eculizumab) of $370.1
million in the second quarter of 2013, an increase of 35 percent from
the same period in 2012.
Revenue performance for the quarter reflected steady additions of new
patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an
increasing number of new patients with atypical hemolytic uremic
syndrome (aHUS) commencing Soliris treatment in the US and Europe.
“In the second quarter, we continued our strong and ongoing global
performance with Soliris in PNH. In the early stages of our aHUS launch,
we were especially pleased to provide Soliris to a steadily growing
number of patients in the US and increasingly in Europe,” said Leonard
Bell, M.D., Chief Executive Officer of Alexion. “Key pipeline
initiatives, including our asfotase alfa program in HPP and our Soliris
programs in NMO and transplant, reached new milestones. As we enter the
second half of the year, we will continue to develop our product
portfolio toward supporting an anticipated series of significant
launches in new indications for Soliris and new products over the next
Second Quarter 2013 Financial Results:
non-GAAP operating results are GAAP operating results adjusted for the
impact of certain items described below. A full reconciliation of GAAP
results to non-GAAP results is included later in this press release.